In Carcinogenesis ; h5-index 60.0
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is largely refractory to available treatments. Identifying key pathways associated with disease aggressiveness and therapeutic resistance may characterize candidate targets to improve patient outcome. We used a strategy of examining the tumors from subset of PDAC patient cohorts with worst survival to understand the underlying mechanisms of aggressive disease progression and to identify candidate molecular targets with potential therapeutic significance. Non-negative matrix factorization (NMF) clustering, using gene expression profile, revealed three patient subsets. A 142-gene signature specific to the subset with the worst patient survival, predicted prognosis and stratified patients with significantly different survival in the test and validation cohorts. Gene-network and pathway analysis of the 142-gene signature revealed dysregulation of Clusterin (CLU) in the most aggressive patient subset in our patient cohort. HNF1B positively regulated CLU, and a lower expression of HNF1B and CLU associated with poor patient survival. Mechanistic and functional analyses revealed that CLU inhibits proliferation, 3D spheroid growth, invasiveness and epithelial-to-mesenchymal transition in pancreatic cancer cell lines. Mechanistically, CLU enhanced proteasomal degradation of EMT-regulator, ZEB1. In addition, orthotopic transplant of CLU-expressing pancreatic cancer cells reduced tumor growth in mice. Furthermore, CLU enhanced sensitivity of pancreatic cancer cells representing aggressive patient subset, to the chemotherapeutic drug gemcitabine. Taken together, HNF1B/CLU axis negatively regulate pancreatic cancer progression and may potentially be useful in designing novel strategies to attenuate disease progression in PDAC patients.
Yang Shouhui, Tang Wei, Azizian Azadeh, Gaedcke Jochen, Ströbel Philipp, Wang Limin, Cawley Helen, Ohara Yuuki, Valenzuela Paloma, Zhang Lin, Lal Trisha, Sinha Sanju, Rupin Eythan, Hanna Nader, Ghadimi B Michael, Hussain S Perwez
2022-Nov-25
Clusterin, HNF1B, Pancreatic cancer, ZEB1, therapeutic targets
